Latanoprostene bunod for open-angle glaucoma or ocular hypertension – first line

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Glaucoma is a common condition that can lead to a loss of vision and eventually blindness. It is usually caused by increased pressure of fluid in the eye (ocular hypertension) when the fluid cannot drain away as well as usual. Glaucoma is usually treated with eye drops, however current treatments are not always effective, and patients may require laser treatment or eye surgery. Latanoprostene bunod is a new drug for the treatment of open-angle glaucoma and ocular hypertension. It is given as an eye drop taken once daily. Some studies have suggested latanoprostene bunod may be useful as a first line treatment and more studies are now aiming to show how well it works and that it is safe to use. If latanoprostene bunod is licensed for use in the UK, it could be a new treatment option for patients with glaucoma which may reduce pressure in the eye and reduce vision loss. If it is more effective than the current first line treatment, it could mean fewer eye drops and fewer visits to clinics would be needed.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/latanoprostene-bunod-for-open-angle-glaucoma-or-ocular-hypertension-first-line/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Glaucoma, Open-Angle; Intraocular Pressure; Ocular Hypertension

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000754

Date abstract record published
14/06/2016